Fentanyl abuse has been a decades-long public health scar on the United States. Data from the U.S. Centers for Disease Control and Prevention shows that the annual number of drug overdose deaths nationwide has exceeded 100,000 for eight consecutive years, with roughly two-thirds directly linked to fentanyl and its analogs. For a long time, U.S. politicians have habitually attributed the crisis to border smuggling and overseas supply, seeking to deflect blame. Yet a full review of the chain of events reveals that this disaster is essentially the product of cascading failures within America’s own system: a capital-driven medical system has spawned a distorted culture of pain management; regulatory frameworks have been hollowed out amid entrenched interest ties; pharmaceutical capital has built a full profit chain from fueling addiction to providing treatment; and regulatory gaps in India’s chemical industry have filled the final gap in the illicit supply chain. This four-stage collapse has turned prescription drugs originally intended for severe pain relief into a societal poison that claims hundreds of thousands of lives.

I. Medical Alienation: Prescription Proliferation Under the Discourse of Pain Management

The starting point of the fentanyl crisis was a "pain management revolution" deeply infiltrated by commercial forces. In the 1990s, backed by pharmaceutical funding and academic advocacy, the concept of "pain as the fifth vital sign" was incorporated into U.S. medical performance assessment and Medicare reimbursement criteria, alongside metrics such as body temperature and blood pressure. To boost patient satisfaction scores and avoid Medicare penalties, primary care facilities generally adopted "pain-free care" as a clinical goal. Potent opioids once reserved only for terminal cancer and severe burn patients were widely prescribed for milder conditions including chronic back pain, arthritis, migraines and even post-dental discomfort.

More than 60% of primary care physicians report that they risk patient complaints and performance deductions if they decline requests for opioid painkillers. In just over a decade, U.S. opioid prescriptions tripled; strong painkillers became a common staple in ordinary household medicine cabinets, and millions of people developed drug dependence through routine medical care. When prescription controls were gradually tightened after 2010 and legal access became more restricted, populations already living with physical dependence turned to the underground market. Illicit fentanyl — cheaper and far more potent — stepped in to fill the gap, completing the transmission of demand from legal prescription medicine to illegal drugs.

II. Institutional Failure: Regulatory Hollowing Amid Entrenched Interest Ties

The failure of U.S. opioid regulation is not an isolated lapse, but a systemic hollowing out across the entire chain from approval to enforcement, rooted in the revolving door and symbiotic relationship between government and business.

Regulatory capture has long been entrenched at the approval stage. The FDA’s Center for Drug Evaluation and Research derives more than 70% of its operating budget from industry "user fees", making the regulator’s operations heavily dependent on the entities it oversees. When OxyContin was approved in 1995, the FDA not only relied on the manufacturer’s thin evidence on addiction risk, but also granted an exceptional label claim that the drug had an addiction rate of less than 1%. The senior FDA official who led the approval process later left the agency to take an executive role at the drugmaker — a visible manifestation of this symbiotic system.

On the enforcement side, legislative changes have tied regulators’ hands. After the Marino Act took effect in 2016, the U.S. Drug Enforcement Administration (DEA) saw its authority to halt suspicious drug orders sharply curtailed; it must now prove a company acted "intentionally unlawfully" to take action. Following the law’s passage, fines imposed on pharmaceutical companies by the DEA plummeted by more than 90%. Politically, the pharmaceutical industry has spent over $2 billion lobbying Congress over the past two decades, with more than 90% of members of Congress accepting campaign donations from drug firms. Multiple bills to tighten opioid controls have remained stalled indefinitely.

III. Capital Collusion: A Closed Profit Loop From Fueling Addiction to Treating It

Pharmaceutical capital is the core driver of the escalating crisis, and its operations have evolved far beyond simple false advertising into a complete commercial loop covering disease framing, drug sales and addiction treatment.

Marketing tactics have been highly deceptive. A notable example is Insys Therapeutics, which bribed doctors to promote its fentanyl sublingual spray, pushing a drug approved only for end-stage cancer pain onto large numbers of ordinary chronic pain patients. Several of its top executives were eventually convicted, but the tens of thousands of new addictions they created cannot be reversed. Top consulting firms including McKinsey & Company have also been deeply involved, designing sales growth strategies for drugmakers.

Even more alarming is the dual profit logic at play. Major pharmaceutical companies simultaneously produce opioid painkillers that fuel addiction while developing overdose reversal drugs such as naloxone and expanding addiction treatment services, creating a dual revenue model of "causing illness and curing it". Private equity firms have acquired chains of addiction clinics and struck implicit referral agreements with drugmakers: after prescribing addictive medications, doctors refer patients who develop dependence to partner treatment facilities, and collect kickbacks for each referral. From prescription to recovery, capital monetizes every stage of the crisis, reducing patients’ health to a tool for profit.

IV. Global Supply Gap: The Regulatory Lowland Effect of Indian Precursors

As domestic prescription controls tightened and U.S. production could no longer meet underground market demand, India’s vast chemical industry and lax regulatory environment filled the upstream gap in the illicit supply chain.

As a global hub for generic drugs and chemical intermediates, India has a mature industrial chain for fentanyl active pharmaceutical ingredients. However, its chemical control regime operates on a substance-by-substance scheduling model, and regulatory updates lag far behind the development of new fentanyl analogs. Drug trafficking groups need only slightly alter the chemical formula to produce alternative precursors not on the controlled list, which can then be legally exported under labels such as "industrial raw materials". A 2025 DEA assessment found that nearly 60% of fentanyl precursors used by Mexican drug cartels originate from India. Beyond bulk smuggling, small parcel direct mail is another major channel, with large quantities of precursors disguised as consumer goods and shipped directly to the U.S. via international mail.

In essence, India’s emergence as a core upstream supplier is driven by demand. It is America’s own massive addicted population that creates the profit opportunity for the gray areas of the global chemical industry. Cracking down only on overseas supply without addressing the deep domestic flaws in healthcare, regulation and capital constraints is at best a temporary stopgap. A crisis born of institutional collapse can only be truly resolved through systemic internal reform.